nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Gefitinib—lung cancer	0.231	1	CrCtD
Bosutinib—P-Glycoprotein Inhibitors—Crizotinib—lung cancer	0.178	1	CiPCiCtD
Bosutinib—Vandetanib—Erlotinib—lung cancer	0.0591	0.406	CrCrCtD
Bosutinib—Vandetanib—Gefitinib—lung cancer	0.0527	0.361	CrCrCtD
Bosutinib—Gefitinib—Erlotinib—lung cancer	0.0339	0.233	CrCrCtD
Bosutinib—TXK—lung cancer	0.0279	0.194	CbGaD
Bosutinib—AXL—lung cancer	0.0249	0.173	CbGaD
Bosutinib—FGR—lung cancer	0.0211	0.147	CbGaD
Bosutinib—MAP2K1—lung cancer	0.0211	0.147	CbGaD
Bosutinib—ERBB3—lung cancer	0.0151	0.105	CbGaD
Bosutinib—ALK—lung cancer	0.0151	0.105	CbGaD
Bosutinib—SRC—lung cancer	0.0101	0.0698	CbGaD
Bosutinib—EGFR—lung cancer	0.00676	0.0469	CbGaD
Bosutinib—LOC400927-CSNK1E—Gefitinib—lung cancer	0.00596	0.0297	CbGbCtD
Bosutinib—CHEK2—Gefitinib—lung cancer	0.00596	0.0297	CbGbCtD
Bosutinib—CSNK1E—Gefitinib—lung cancer	0.00596	0.0297	CbGbCtD
Bosutinib—FES—Crizotinib—lung cancer	0.00505	0.0251	CbGbCtD
Bosutinib—CASK—Crizotinib—lung cancer	0.00505	0.0251	CbGbCtD
Bosutinib—FER—Crizotinib—lung cancer	0.00505	0.0251	CbGbCtD
Bosutinib—IKBKE—Crizotinib—lung cancer	0.00505	0.0251	CbGbCtD
Bosutinib—DSTYK—Crizotinib—lung cancer	0.00505	0.0251	CbGbCtD
Bosutinib—IRAK4—Gefitinib—lung cancer	0.00473	0.0236	CbGbCtD
Bosutinib—ERBB3—Gefitinib—lung cancer	0.00473	0.0236	CbGbCtD
Bosutinib—STK3—Crizotinib—lung cancer	0.00365	0.0182	CbGbCtD
Bosutinib—SIK2—Crizotinib—lung cancer	0.00365	0.0182	CbGbCtD
Bosutinib—MAP4K2—Crizotinib—lung cancer	0.00365	0.0182	CbGbCtD
Bosutinib—PTK2—Crizotinib—lung cancer	0.00365	0.0182	CbGbCtD
Bosutinib—TBK1—Crizotinib—lung cancer	0.00365	0.0182	CbGbCtD
Bosutinib—STK4—Crizotinib—lung cancer	0.00365	0.0182	CbGbCtD
Bosutinib—MAP3K12—Crizotinib—lung cancer	0.00365	0.0182	CbGbCtD
Bosutinib—MERTK—Crizotinib—lung cancer	0.00365	0.0182	CbGbCtD
Bosutinib—RPS6KB1—Crizotinib—lung cancer	0.00365	0.0182	CbGbCtD
Bosutinib—TXK—Crizotinib—lung cancer	0.00365	0.0182	CbGbCtD
Bosutinib—ULK3—Erlotinib—lung cancer	0.00352	0.0175	CbGbCtD
Bosutinib—IRAK1—Gefitinib—lung cancer	0.00342	0.017	CbGbCtD
Bosutinib—HIPK4—Gefitinib—lung cancer	0.00302	0.0151	CbGbCtD
Bosutinib—BMP2K—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—TYRO3—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—PTK2B—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—MAP4K1—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—EPHA3—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—EPHA4—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—AXL—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—EPHA5—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—TNK2—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—EPHB4—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—ALK—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—STK35—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—NUAK2—Crizotinib—lung cancer	0.0029	0.0144	CbGbCtD
Bosutinib—STK10—Gefitinib—lung cancer	0.00272	0.0135	CbGbCtD
Bosutinib—EGFR—Gefitinib—lung cancer	0.00272	0.0135	CbGbCtD
Bosutinib—MAP2K5—Gefitinib—lung cancer	0.00247	0.0123	CbGbCtD
Bosutinib—EPHA2—Crizotinib—lung cancer	0.00243	0.0121	CbGbCtD
Bosutinib—EPHA8—Crizotinib—lung cancer	0.00243	0.0121	CbGbCtD
Bosutinib—SLK—Crizotinib—lung cancer	0.00243	0.0121	CbGbCtD
Bosutinib—MAP4K5—Crizotinib—lung cancer	0.00243	0.0121	CbGbCtD
Bosutinib—YES1—Crizotinib—lung cancer	0.00243	0.0121	CbGbCtD
Bosutinib—MAP3K3—Crizotinib—lung cancer	0.00243	0.0121	CbGbCtD
Bosutinib—TAOK3—Crizotinib—lung cancer	0.00243	0.0121	CbGbCtD
Bosutinib—SLK—Erlotinib—lung cancer	0.00234	0.0117	CbGbCtD
Bosutinib—MAP3K19—Gefitinib—lung cancer	0.00227	0.0113	CbGbCtD
Bosutinib—FGR—Crizotinib—lung cancer	0.0021	0.0104	CbGbCtD
Bosutinib—IRAK1—Crizotinib—lung cancer	0.0021	0.0104	CbGbCtD
Bosutinib—MAP3K2—Crizotinib—lung cancer	0.0021	0.0104	CbGbCtD
Bosutinib—ABCB1—lung cancer	0.00205	0.0143	CbGaD
Bosutinib—LYN—Crizotinib—lung cancer	0.00185	0.00923	CbGbCtD
Bosutinib—SRC—Crizotinib—lung cancer	0.00185	0.00923	CbGbCtD
Bosutinib—BLK—Crizotinib—lung cancer	0.00185	0.00923	CbGbCtD
Bosutinib—HIPK4—Erlotinib—lung cancer	0.00179	0.0089	CbGbCtD
Bosutinib—ABL2—Crizotinib—lung cancer	0.00167	0.00829	CbGbCtD
Bosutinib—STK10—Crizotinib—lung cancer	0.00167	0.00829	CbGbCtD
Bosutinib—CSF1R—Crizotinib—lung cancer	0.00167	0.00829	CbGbCtD
Bosutinib—EGFR—Erlotinib—lung cancer	0.00161	0.008	CbGbCtD
Bosutinib—ABL2—Erlotinib—lung cancer	0.00161	0.008	CbGbCtD
Bosutinib—STK10—Erlotinib—lung cancer	0.00161	0.008	CbGbCtD
Bosutinib—LCK—Crizotinib—lung cancer	0.00152	0.00755	CbGbCtD
Bosutinib—MAP2K5—Erlotinib—lung cancer	0.00146	0.00728	CbGbCtD
Bosutinib—MAP3K19—Crizotinib—lung cancer	0.00139	0.00694	CbGbCtD
Bosutinib—MAP3K19—Erlotinib—lung cancer	0.00134	0.00669	CbGbCtD
Bosutinib—ABL1—Crizotinib—lung cancer	0.0012	0.006	CbGbCtD
Bosutinib—ABL1—Erlotinib—lung cancer	0.00116	0.00578	CbGbCtD
Bosutinib—EGFR—Docetaxel—lung cancer	0.00106	0.00529	CbGbCtD
Bosutinib—Vandetanib—AXL—lung cancer	0.000209	0.183	CrCbGaD
Bosutinib—Vandetanib—FGR—lung cancer	0.000178	0.156	CrCbGaD
Bosutinib—ABCB1—Topotecan—lung cancer	0.000177	0.000881	CbGbCtD
Bosutinib—ABCB1—Gefitinib—lung cancer	0.000162	0.000806	CbGbCtD
Bosutinib—Vandetanib—ERBB3—lung cancer	0.000127	0.111	CrCbGaD
Bosutinib—ABCB1—Vinorelbine—lung cancer	0.000125	0.000621	CbGbCtD
Bosutinib—Gefitinib—ERBB3—lung cancer	0.000121	0.106	CrCbGaD
Bosutinib—CYP3A4—Topotecan—lung cancer	0.000106	0.000528	CbGbCtD
Bosutinib—ROCK1—Irinotecan—Topotecan—lung cancer	0.000101	0.111	CbGdCrCtD
Bosutinib—ABCB1—Crizotinib—lung cancer	9.92e-05	0.000494	CbGbCtD
Bosutinib—CYP3A4—Gefitinib—lung cancer	9.7e-05	0.000483	CbGbCtD
Bosutinib—ABCB1—Gemcitabine—lung cancer	9.7e-05	0.000483	CbGbCtD
Bosutinib—ABCB1—Erlotinib—lung cancer	9.57e-05	0.000476	CbGbCtD
Bosutinib—CYP3A4—Teniposide—lung cancer	9.4e-05	0.000468	CbGbCtD
Bosutinib—MAP4K4—Irinotecan—Topotecan—lung cancer	8.97e-05	0.099	CbGdCrCtD
Bosutinib—ABCB1—Paclitaxel—lung cancer	8.76e-05	0.000436	CbGbCtD
Bosutinib—ABCB1—Irinotecan—lung cancer	8.64e-05	0.00043	CbGbCtD
Bosutinib—Vandetanib—SRC—lung cancer	8.47e-05	0.0742	CrCbGaD
Bosutinib—Vandetanib—KDR—lung cancer	7.95e-05	0.0697	CrCbGaD
Bosutinib—ABCB1—Vinblastine—lung cancer	7.68e-05	0.000382	CbGbCtD
Bosutinib—EPHB2—Irinotecan—Topotecan—lung cancer	7.63e-05	0.0842	CbGdCrCtD
Bosutinib—CYP3A4—Vinorelbine—lung cancer	7.47e-05	0.000372	CbGbCtD
Bosutinib—ABCB1—Cisplatin—lung cancer	7.04e-05	0.000351	CbGbCtD
Bosutinib—ABCB1—Etoposide—lung cancer	6.92e-05	0.000345	CbGbCtD
Bosutinib—Vandetanib—VEGFA—lung cancer	6.74e-05	0.0591	CrCbGaD
Bosutinib—ABCB1—Docetaxel—lung cancer	6.33e-05	0.000315	CbGbCtD
Bosutinib—CYP3A4—Crizotinib—lung cancer	5.94e-05	0.000296	CbGbCtD
Bosutinib—WEE1—Paclitaxel—Docetaxel—lung cancer	5.87e-05	0.0648	CbGdCrCtD
Bosutinib—CASK—Irinotecan—Topotecan—lung cancer	5.78e-05	0.0638	CbGdCrCtD
Bosutinib—CYP3A4—Erlotinib—lung cancer	5.73e-05	0.000285	CbGbCtD
Bosutinib—Vandetanib—EGFR—lung cancer	5.69e-05	0.0498	CrCbGaD
Bosutinib—Gefitinib—EGFR—lung cancer	5.41e-05	0.0474	CrCbGaD
Bosutinib—CYP3A4—Paclitaxel—lung cancer	5.25e-05	0.000261	CbGbCtD
Bosutinib—CYP3A4—Irinotecan—lung cancer	5.18e-05	0.000258	CbGbCtD
Bosutinib—CAMK1D—lung—lung cancer	4.97e-05	0.00205	CbGeAlD
Bosutinib—IRAK4—trachea—lung cancer	4.96e-05	0.00204	CbGeAlD
Bosutinib—SRC—respiratory system—lung cancer	4.94e-05	0.00203	CbGeAlD
Bosutinib—STK24—lung—lung cancer	4.91e-05	0.00202	CbGeAlD
Bosutinib—EPHA4—trachea—lung cancer	4.91e-05	0.00202	CbGeAlD
Bosutinib—ERBB3—trachea—lung cancer	4.86e-05	0.002	CbGeAlD
Bosutinib—EPHB4—epithelium—lung cancer	4.85e-05	0.002	CbGeAlD
Bosutinib—ULK3—trachea—lung cancer	4.85e-05	0.002	CbGeAlD
Bosutinib—TLK1—lymph node—lung cancer	4.85e-05	0.002	CbGeAlD
Bosutinib—SLK—bronchus—lung cancer	4.82e-05	0.00198	CbGeAlD
Bosutinib—CDK2—Paclitaxel—Docetaxel—lung cancer	4.78e-05	0.0528	CbGdCrCtD
Bosutinib—EPHB4—bronchus—lung cancer	4.78e-05	0.00197	CbGeAlD
Bosutinib—PRKCQ—lymph node—lung cancer	4.78e-05	0.00197	CbGeAlD
Bosutinib—MAP3K7—trachea—lung cancer	4.77e-05	0.00196	CbGeAlD
Bosutinib—EPHA2—epithelium—lung cancer	4.76e-05	0.00196	CbGeAlD
Bosutinib—FER—lung—lung cancer	4.75e-05	0.00196	CbGeAlD
Bosutinib—ALK—lung—lung cancer	4.75e-05	0.00196	CbGeAlD
Bosutinib—ABCB1—Doxorubicin—lung cancer	4.72e-05	0.000235	CbGbCtD
Bosutinib—TBK1—trachea—lung cancer	4.72e-05	0.00194	CbGeAlD
Bosutinib—PTK2—trachea—lung cancer	4.72e-05	0.00194	CbGeAlD
Bosutinib—EPHA2—bronchus—lung cancer	4.69e-05	0.00193	CbGeAlD
Bosutinib—FYN—bronchus—lung cancer	4.68e-05	0.00193	CbGeAlD
Bosutinib—SIK1—cardiac atrium—lung cancer	4.66e-05	0.00192	CbGeAlD
Bosutinib—MAP3K19—lung—lung cancer	4.66e-05	0.00192	CbGeAlD
Bosutinib—MAP4K1—lung—lung cancer	4.66e-05	0.00192	CbGeAlD
Bosutinib—BTK—lung—lung cancer	4.63e-05	0.00191	CbGeAlD
Bosutinib—PTK2—Irinotecan—Topotecan—lung cancer	4.62e-05	0.051	CbGdCrCtD
Bosutinib—EPHA4—cardiac atrium—lung cancer	4.61e-05	0.0019	CbGeAlD
Bosutinib—MERTK—bone marrow—lung cancer	4.61e-05	0.0019	CbGeAlD
Bosutinib—CYP3A4—Vinblastine—lung cancer	4.6e-05	0.000229	CbGbCtD
Bosutinib—MAP3K3—bronchus—lung cancer	4.58e-05	0.00188	CbGeAlD
Bosutinib—MAP4K5—bronchus—lung cancer	4.58e-05	0.00188	CbGeAlD
Bosutinib—ABCB1—Methotrexate—lung cancer	4.57e-05	0.000228	CbGbCtD
Bosutinib—TNK2—lung—lung cancer	4.57e-05	0.00188	CbGeAlD
Bosutinib—ULK3—cardiac atrium—lung cancer	4.56e-05	0.00188	CbGeAlD
Bosutinib—MAP2K2—cardiac atrium—lung cancer	4.56e-05	0.00188	CbGeAlD
Bosutinib—RPS6KB1—trachea—lung cancer	4.54e-05	0.00187	CbGeAlD
Bosutinib—MAP4K4—bone marrow—lung cancer	4.52e-05	0.00186	CbGeAlD
Bosutinib—LCK—trachea—lung cancer	4.51e-05	0.00186	CbGeAlD
Bosutinib—MAP4K2—lung—lung cancer	4.5e-05	0.00185	CbGeAlD
Bosutinib—BCR—bone marrow—lung cancer	4.49e-05	0.00185	CbGeAlD
Bosutinib—NUAK2—bone marrow—lung cancer	4.49e-05	0.00185	CbGeAlD
Bosutinib—AXL—trachea—lung cancer	4.49e-05	0.00185	CbGeAlD
Bosutinib—DSTYK—lymph node—lung cancer	4.48e-05	0.00185	CbGeAlD
Bosutinib—CLK3—lymph node—lung cancer	4.48e-05	0.00185	CbGeAlD
Bosutinib—BMX—lymph node—lung cancer	4.48e-05	0.00185	CbGeAlD
Bosutinib—MAP3K7—cardiac atrium—lung cancer	4.48e-05	0.00185	CbGeAlD
Bosutinib—ERBB4—lung—lung cancer	4.44e-05	0.00183	CbGeAlD
Bosutinib—STK3—lung—lung cancer	4.44e-05	0.00183	CbGeAlD
Bosutinib—CSF1R—respiratory system—lung cancer	4.43e-05	0.00183	CbGeAlD
Bosutinib—BLK—lymph node—lung cancer	4.43e-05	0.00183	CbGeAlD
Bosutinib—TBK1—cardiac atrium—lung cancer	4.43e-05	0.00182	CbGeAlD
Bosutinib—ROCK1—lung—lung cancer	4.38e-05	0.00181	CbGeAlD
Bosutinib—PHKG1—lymph node—lung cancer	4.38e-05	0.00181	CbGeAlD
Bosutinib—CASK—lymph node—lung cancer	4.38e-05	0.00181	CbGeAlD
Bosutinib—MAP2K1—bone marrow—lung cancer	4.37e-05	0.0018	CbGeAlD
Bosutinib—CSK—bone marrow—lung cancer	4.34e-05	0.00179	CbGeAlD
Bosutinib—EIF2AK1—lymph node—lung cancer	4.34e-05	0.00179	CbGeAlD
Bosutinib—SLK—trachea—lung cancer	4.32e-05	0.00178	CbGeAlD
Bosutinib—CSNK1A1—bone marrow—lung cancer	4.31e-05	0.00178	CbGeAlD
Bosutinib—EPHB4—trachea—lung cancer	4.29e-05	0.00177	CbGeAlD
Bosutinib—HCK—bone marrow—lung cancer	4.29e-05	0.00176	CbGeAlD
Bosutinib—CLK1—bone marrow—lung cancer	4.29e-05	0.00176	CbGeAlD
Bosutinib—RPS6KB1—cardiac atrium—lung cancer	4.26e-05	0.00176	CbGeAlD
Bosutinib—BMPR2—lung—lung cancer	4.26e-05	0.00175	CbGeAlD
Bosutinib—TXK—lymph node—lung cancer	4.24e-05	0.00175	CbGeAlD
Bosutinib—YES1—bronchus—lung cancer	4.23e-05	0.00174	CbGeAlD
Bosutinib—EPHB3—lung—lung cancer	4.23e-05	0.00174	CbGeAlD
Bosutinib—STK36—lung—lung cancer	4.23e-05	0.00174	CbGeAlD
Bosutinib—AXL—cardiac atrium—lung cancer	4.22e-05	0.00174	CbGeAlD
Bosutinib—EPHA2—trachea—lung cancer	4.21e-05	0.00173	CbGeAlD
Bosutinib—CAMK2G—bone marrow—lung cancer	4.21e-05	0.00173	CbGeAlD
Bosutinib—BMP2K—bone marrow—lung cancer	4.21e-05	0.00173	CbGeAlD
Bosutinib—FYN—trachea—lung cancer	4.2e-05	0.00173	CbGeAlD
Bosutinib—VRK2—lymph node—lung cancer	4.2e-05	0.00173	CbGeAlD
Bosutinib—FES—lymph node—lung cancer	4.2e-05	0.00173	CbGeAlD
Bosutinib—STK10—bronchus—lung cancer	4.19e-05	0.00172	CbGeAlD
Bosutinib—MERTK—lung—lung cancer	4.18e-05	0.00172	CbGeAlD
Bosutinib—TAOK3—bronchus—lung cancer	4.17e-05	0.00172	CbGeAlD
Bosutinib—LRRK2—bone marrow—lung cancer	4.17e-05	0.00172	CbGeAlD
Bosutinib—Vandetanib—ABCG2—lung cancer	4.16e-05	0.0364	CrCbGaD
Bosutinib—CYP3A4—Etoposide—lung cancer	4.15e-05	0.000206	CbGbCtD
Bosutinib—SRC—epithelium—lung cancer	4.13e-05	0.0017	CbGeAlD
Bosutinib—TNIK—lymph node—lung cancer	4.12e-05	0.0017	CbGeAlD
Bosutinib—SYK—lymph node—lung cancer	4.12e-05	0.0017	CbGeAlD
Bosutinib—MAP3K3—trachea—lung cancer	4.11e-05	0.00169	CbGeAlD
Bosutinib—MAP4K5—trachea—lung cancer	4.11e-05	0.00169	CbGeAlD
Bosutinib—MAP4K4—lung—lung cancer	4.1e-05	0.00169	CbGeAlD
Bosutinib—CDK2—lymph node—lung cancer	4.08e-05	0.00168	CbGeAlD
Bosutinib—BCR—lung—lung cancer	4.07e-05	0.00168	CbGeAlD
Bosutinib—NUAK2—lung—lung cancer	4.07e-05	0.00168	CbGeAlD
Bosutinib—PTK2B—bone marrow—lung cancer	4.06e-05	0.00167	CbGeAlD
Bosutinib—SLK—cardiac atrium—lung cancer	4.06e-05	0.00167	CbGeAlD
Bosutinib—STK26—lymph node—lung cancer	4.04e-05	0.00167	CbGeAlD
Bosutinib—MAP3K12—lung—lung cancer	4.04e-05	0.00166	CbGeAlD
Bosutinib—EPHB4—cardiac atrium—lung cancer	4.03e-05	0.00166	CbGeAlD
Bosutinib—MAP2K1—lung—lung cancer	3.96e-05	0.00163	CbGeAlD
Bosutinib—STK35—lung—lung cancer	3.96e-05	0.00163	CbGeAlD
Bosutinib—EPHA2—cardiac atrium—lung cancer	3.96e-05	0.00163	CbGeAlD
Bosutinib—FYN—cardiac atrium—lung cancer	3.95e-05	0.00163	CbGeAlD
Bosutinib—Gefitinib—ABCG2—lung cancer	3.95e-05	0.0346	CrCbGaD
Bosutinib—SIK1—bone marrow—lung cancer	3.93e-05	0.00162	CbGeAlD
Bosutinib—IRAK4—bone marrow—lung cancer	3.93e-05	0.00162	CbGeAlD
Bosutinib—CSK—lung—lung cancer	3.93e-05	0.00162	CbGeAlD
Bosutinib—PDGFRB—respiratory system—lung cancer	3.93e-05	0.00162	CbGeAlD
Bosutinib—CSNK1A1—lung—lung cancer	3.91e-05	0.00161	CbGeAlD
Bosutinib—CHEK2—lymph node—lung cancer	3.91e-05	0.00161	CbGeAlD
Bosutinib—HCK—lung—lung cancer	3.88e-05	0.0016	CbGeAlD
Bosutinib—CLK1—lung—lung cancer	3.88e-05	0.0016	CbGeAlD
Bosutinib—DMPK—lymph node—lung cancer	3.87e-05	0.0016	CbGeAlD
Bosutinib—WEE1—lymph node—lung cancer	3.87e-05	0.0016	CbGeAlD
Bosutinib—MAP4K5—cardiac atrium—lung cancer	3.86e-05	0.00159	CbGeAlD
Bosutinib—MAP3K3—cardiac atrium—lung cancer	3.86e-05	0.00159	CbGeAlD
Bosutinib—ABL2—lung—lung cancer	3.86e-05	0.00159	CbGeAlD
Bosutinib—ULK3—bone marrow—lung cancer	3.85e-05	0.00158	CbGeAlD
Bosutinib—MAP2K2—bone marrow—lung cancer	3.85e-05	0.00158	CbGeAlD
Bosutinib—MAP3K2—bone marrow—lung cancer	3.82e-05	0.00157	CbGeAlD
Bosutinib—CAMK2G—lung—lung cancer	3.81e-05	0.00157	CbGeAlD
Bosutinib—BMP2K—lung—lung cancer	3.81e-05	0.00157	CbGeAlD
Bosutinib—CYP3A4—Docetaxel—lung cancer	3.79e-05	0.000189	CbGbCtD
Bosutinib—YES1—trachea—lung cancer	3.79e-05	0.00156	CbGeAlD
Bosutinib—MAP3K7—bone marrow—lung cancer	3.78e-05	0.00156	CbGeAlD
Bosutinib—LRRK2—lung—lung cancer	3.78e-05	0.00156	CbGeAlD
Bosutinib—EGFR—lung—lung cancer	3.77e-05	0.00155	CbGeAlD
Bosutinib—TAOK3—trachea—lung cancer	3.75e-05	0.00154	CbGeAlD
Bosutinib—TBK1—bone marrow—lung cancer	3.74e-05	0.00154	CbGeAlD
Bosutinib—MAP2K5—bronchus—lung cancer	3.74e-05	0.00154	CbGeAlD
Bosutinib—STK25—Afatinib—Gefitinib—lung cancer	3.7e-05	0.0408	CbGdCrCtD
Bosutinib—STK25—lymph node—lung cancer	3.7e-05	0.00152	CbGeAlD
Bosutinib—PTK2B—lung—lung cancer	3.68e-05	0.00152	CbGeAlD
Bosutinib—EPHA3—lymph node—lung cancer	3.67e-05	0.00151	CbGeAlD
Bosutinib—IRAK1—bone marrow—lung cancer	3.67e-05	0.00151	CbGeAlD
Bosutinib—CSF1R—bronchus—lung cancer	3.65e-05	0.0015	CbGeAlD
Bosutinib—CSNK1E—lung—lung cancer	3.62e-05	0.00149	CbGeAlD
Bosutinib—RPS6KB1—bone marrow—lung cancer	3.6e-05	0.00148	CbGeAlD
Bosutinib—PLK2—lymph node—lung cancer	3.6e-05	0.00148	CbGeAlD
Bosutinib—FGR—bone marrow—lung cancer	3.58e-05	0.00147	CbGeAlD
Bosutinib—LCK—bone marrow—lung cancer	3.58e-05	0.00147	CbGeAlD
Bosutinib—SIK3—lymph node—lung cancer	3.57e-05	0.00147	CbGeAlD
Bosutinib—SIK1—lung—lung cancer	3.56e-05	0.00147	CbGeAlD
Bosutinib—IRAK4—lung—lung cancer	3.56e-05	0.00147	CbGeAlD
Bosutinib—YES1—cardiac atrium—lung cancer	3.56e-05	0.00147	CbGeAlD
Bosutinib—EPHA4—lung—lung cancer	3.53e-05	0.00145	CbGeAlD
Bosutinib—TAOK3—cardiac atrium—lung cancer	3.52e-05	0.00145	CbGeAlD
Bosutinib—ABL1—respiratory system—lung cancer	3.51e-05	0.00144	CbGeAlD
Bosutinib—ERBB3—lung—lung cancer	3.49e-05	0.00144	CbGeAlD
Bosutinib—MAP2K2—lung—lung cancer	3.49e-05	0.00144	CbGeAlD
Bosutinib—ULK3—lung—lung cancer	3.49e-05	0.00144	CbGeAlD
Bosutinib—MAP3K2—lung—lung cancer	3.46e-05	0.00143	CbGeAlD
Bosutinib—STK4—lymph node—lung cancer	3.44e-05	0.00142	CbGeAlD
Bosutinib—SLK—bone marrow—lung cancer	3.43e-05	0.00141	CbGeAlD
Bosutinib—SRC—cardiac atrium—lung cancer	3.43e-05	0.00141	CbGeAlD
Bosutinib—MAP3K7—lung—lung cancer	3.43e-05	0.00141	CbGeAlD
Bosutinib—EPHB4—bone marrow—lung cancer	3.4e-05	0.0014	CbGeAlD
Bosutinib—CAMK1D—lymph node—lung cancer	3.4e-05	0.0014	CbGeAlD
Bosutinib—TBK1—lung—lung cancer	3.39e-05	0.0014	CbGeAlD
Bosutinib—PTK2—lung—lung cancer	3.39e-05	0.0014	CbGeAlD
Bosutinib—STK24—Teniposide—Etoposide—lung cancer	3.36e-05	0.0371	CbGdCrCtD
Bosutinib—STK24—lymph node—lung cancer	3.36e-05	0.00138	CbGeAlD
Bosutinib—MAP2K5—trachea—lung cancer	3.36e-05	0.00138	CbGeAlD
Bosutinib—FYN—bone marrow—lung cancer	3.33e-05	0.00137	CbGeAlD
Bosutinib—IRAK1—lung—lung cancer	3.32e-05	0.00137	CbGeAlD
Bosutinib—PDGFRB—epithelium—lung cancer	3.29e-05	0.00135	CbGeAlD
Bosutinib—CSF1R—trachea—lung cancer	3.28e-05	0.00135	CbGeAlD
Bosutinib—RPS6KB1—lung—lung cancer	3.26e-05	0.00134	CbGeAlD
Bosutinib—MAP3K3—bone marrow—lung cancer	3.26e-05	0.00134	CbGeAlD
Bosutinib—MAP4K5—bone marrow—lung cancer	3.26e-05	0.00134	CbGeAlD
Bosutinib—ALK—lymph node—lung cancer	3.25e-05	0.00134	CbGeAlD
Bosutinib—FER—lymph node—lung cancer	3.25e-05	0.00134	CbGeAlD
Bosutinib—LCK—lung—lung cancer	3.24e-05	0.00133	CbGeAlD
Bosutinib—FGR—lung—lung cancer	3.24e-05	0.00133	CbGeAlD
Bosutinib—PDGFRB—bronchus—lung cancer	3.24e-05	0.00133	CbGeAlD
Bosutinib—AXL—lung—lung cancer	3.23e-05	0.00133	CbGeAlD
Bosutinib—MAP4K1—lymph node—lung cancer	3.18e-05	0.00131	CbGeAlD
Bosutinib—BTK—lymph node—lung cancer	3.17e-05	0.00131	CbGeAlD
Bosutinib—MAP2K5—cardiac atrium—lung cancer	3.15e-05	0.0013	CbGeAlD
Bosutinib—TNK2—lymph node—lung cancer	3.12e-05	0.00129	CbGeAlD
Bosutinib—SLK—lung—lung cancer	3.11e-05	0.00128	CbGeAlD
Bosutinib—Gefitinib—CYP1A1—lung cancer	3.09e-05	0.0271	CrCbGaD
Bosutinib—EPHB4—lung—lung cancer	3.08e-05	0.00127	CbGeAlD
Bosutinib—MAP4K2—lymph node—lung cancer	3.08e-05	0.00127	CbGeAlD
Bosutinib—CSF1R—cardiac atrium—lung cancer	3.08e-05	0.00127	CbGeAlD
Bosutinib—STK3—lymph node—lung cancer	3.04e-05	0.00125	CbGeAlD
Bosutinib—EPHA2—lung—lung cancer	3.03e-05	0.00125	CbGeAlD
Bosutinib—FYN—lung—lung cancer	3.02e-05	0.00124	CbGeAlD
Bosutinib—YES1—bone marrow—lung cancer	3.01e-05	0.00124	CbGeAlD
Bosutinib—STK10—bone marrow—lung cancer	2.98e-05	0.00123	CbGeAlD
Bosutinib—TAOK3—bone marrow—lung cancer	2.97e-05	0.00122	CbGeAlD
Bosutinib—MAP4K5—lung—lung cancer	2.95e-05	0.00122	CbGeAlD
Bosutinib—MAP3K3—lung—lung cancer	2.95e-05	0.00122	CbGeAlD
Bosutinib—PKMYT1—Afatinib—Gefitinib—lung cancer	2.94e-05	0.0324	CbGdCrCtD
Bosutinib—CHEK2—Docetaxel—Paclitaxel—lung cancer	2.94e-05	0.0324	CbGdCrCtD
Bosutinib—BMPR2—lymph node—lung cancer	2.91e-05	0.0012	CbGeAlD
Bosutinib—PDGFRB—trachea—lung cancer	2.91e-05	0.0012	CbGeAlD
Bosutinib—EPHB3—lymph node—lung cancer	2.89e-05	0.00119	CbGeAlD
Bosutinib—STK36—lymph node—lung cancer	2.89e-05	0.00119	CbGeAlD
Bosutinib—ABL1—bronchus—lung cancer	2.88e-05	0.00119	CbGeAlD
Bosutinib—MERTK—lymph node—lung cancer	2.86e-05	0.00118	CbGeAlD
Bosutinib—CYP3A4—Doxorubicin—lung cancer	2.83e-05	0.000141	CbGbCtD
Bosutinib—MAP4K4—lymph node—lung cancer	2.8e-05	0.00115	CbGeAlD
Bosutinib—BCR—lymph node—lung cancer	2.78e-05	0.00115	CbGeAlD
Bosutinib—NUAK2—lymph node—lung cancer	2.78e-05	0.00115	CbGeAlD
Bosutinib—MAP3K12—lymph node—lung cancer	2.76e-05	0.00114	CbGeAlD
Bosutinib—PDGFRB—cardiac atrium—lung cancer	2.73e-05	0.00112	CbGeAlD
Bosutinib—YES1—lung—lung cancer	2.73e-05	0.00112	CbGeAlD
Bosutinib—MAP2K1—lymph node—lung cancer	2.71e-05	0.00112	CbGeAlD
Bosutinib—STK35—lymph node—lung cancer	2.71e-05	0.00112	CbGeAlD
Bosutinib—STK10—lung—lung cancer	2.7e-05	0.00111	CbGeAlD
Bosutinib—TAOK3—lung—lung cancer	2.69e-05	0.00111	CbGeAlD
Bosutinib—CSK—lymph node—lung cancer	2.69e-05	0.00111	CbGeAlD
Bosutinib—CSNK1A1—lymph node—lung cancer	2.67e-05	0.0011	CbGeAlD
Bosutinib—HCK—lymph node—lung cancer	2.66e-05	0.00109	CbGeAlD
Bosutinib—CLK1—lymph node—lung cancer	2.66e-05	0.00109	CbGeAlD
Bosutinib—CDK2—Vinblastine—Vinorelbine—lung cancer	2.65e-05	0.0292	CbGdCrCtD
Bosutinib—ABL2—lymph node—lung cancer	2.64e-05	0.00109	CbGeAlD
Bosutinib—SRC—lung—lung cancer	2.62e-05	0.00108	CbGeAlD
Bosutinib—CAMK2G—lymph node—lung cancer	2.61e-05	0.00107	CbGeAlD
Bosutinib—BMP2K—lymph node—lung cancer	2.61e-05	0.00107	CbGeAlD
Bosutinib—CSF1R—bone marrow—lung cancer	2.6e-05	0.00107	CbGeAlD
Bosutinib—ABL1—trachea—lung cancer	2.59e-05	0.00107	CbGeAlD
Bosutinib—LRRK2—lymph node—lung cancer	2.58e-05	0.00106	CbGeAlD
Bosutinib—EGFR—lymph node—lung cancer	2.58e-05	0.00106	CbGeAlD
Bosutinib—PTK2B—lymph node—lung cancer	2.52e-05	0.00104	CbGeAlD
Bosutinib—CSNK1E—lymph node—lung cancer	2.48e-05	0.00102	CbGeAlD
Bosutinib—SIK1—lymph node—lung cancer	2.44e-05	0.001	CbGeAlD
Bosutinib—IRAK4—lymph node—lung cancer	2.44e-05	0.001	CbGeAlD
Bosutinib—ABL1—cardiac atrium—lung cancer	2.43e-05	0.001	CbGeAlD
Bosutinib—EPHA4—lymph node—lung cancer	2.41e-05	0.000994	CbGeAlD
Bosutinib—MAP2K5—lung—lung cancer	2.41e-05	0.000994	CbGeAlD
Bosutinib—ERBB3—lymph node—lung cancer	2.39e-05	0.000984	CbGeAlD
Bosutinib—MAP2K2—lymph node—lung cancer	2.38e-05	0.000982	CbGeAlD
Bosutinib—ULK3—lymph node—lung cancer	2.38e-05	0.000982	CbGeAlD
Bosutinib—MAP3K2—lymph node—lung cancer	2.37e-05	0.000975	CbGeAlD
Bosutinib—CSF1R—lung—lung cancer	2.35e-05	0.00097	CbGeAlD
Bosutinib—ERBB3—Podofilox—Teniposide—lung cancer	2.35e-05	0.0259	CbGdCrCtD
Bosutinib—MAP3K7—lymph node—lung cancer	2.34e-05	0.000966	CbGeAlD
Bosutinib—PTK2—lymph node—lung cancer	2.32e-05	0.000955	CbGeAlD
Bosutinib—TBK1—lymph node—lung cancer	2.32e-05	0.000955	CbGeAlD
Bosutinib—PDGFRB—bone marrow—lung cancer	2.3e-05	0.000949	CbGeAlD
Bosutinib—IRAK1—lymph node—lung cancer	2.27e-05	0.000936	CbGeAlD
Bosutinib—RPS6KB1—lymph node—lung cancer	2.23e-05	0.000918	CbGeAlD
Bosutinib—LCK—lymph node—lung cancer	2.22e-05	0.000913	CbGeAlD
Bosutinib—FGR—lymph node—lung cancer	2.22e-05	0.000913	CbGeAlD
Bosutinib—AXL—lymph node—lung cancer	2.21e-05	0.000909	CbGeAlD
Bosutinib—CASK—Teniposide—Etoposide—lung cancer	2.16e-05	0.0239	CbGdCrCtD
Bosutinib—SLK—lymph node—lung cancer	2.12e-05	0.000875	CbGeAlD
Bosutinib—EPHB4—lymph node—lung cancer	2.11e-05	0.000869	CbGeAlD
Bosutinib—PDGFRB—lung—lung cancer	2.09e-05	0.00086	CbGeAlD
Bosutinib—EPHA2—lymph node—lung cancer	2.07e-05	0.000852	CbGeAlD
Bosutinib—FYN—lymph node—lung cancer	2.07e-05	0.000851	CbGeAlD
Bosutinib—ABL1—bone marrow—lung cancer	2.05e-05	0.000846	CbGeAlD
Bosutinib—MAP3K3—lymph node—lung cancer	2.02e-05	0.000831	CbGeAlD
Bosutinib—MAP4K5—lymph node—lung cancer	2.02e-05	0.000831	CbGeAlD
Bosutinib—ABL1—Topotecan—Irinotecan—lung cancer	1.99e-05	0.022	CbGdCrCtD
Bosutinib—CHEK2—Vindesine—Vinorelbine—lung cancer	1.87e-05	0.0206	CbGdCrCtD
Bosutinib—YES1—lymph node—lung cancer	1.86e-05	0.000768	CbGeAlD
Bosutinib—ABL1—lung—lung cancer	1.86e-05	0.000767	CbGeAlD
Bosutinib—STK10—lymph node—lung cancer	1.85e-05	0.000761	CbGeAlD
Bosutinib—TAOK3—lymph node—lung cancer	1.84e-05	0.000758	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—lung cancer	1.82e-05	0.0201	CbGdCrCtD
Bosutinib—Vandetanib—ALB—lung cancer	1.81e-05	0.0159	CrCbGaD
Bosutinib—SRC—lymph node—lung cancer	1.79e-05	0.000739	CbGeAlD
Bosutinib—Gefitinib—ALB—lung cancer	1.72e-05	0.0151	CrCbGaD
Bosutinib—MAP2K5—lymph node—lung cancer	1.65e-05	0.00068	CbGeAlD
Bosutinib—Gefitinib—ABCB1—lung cancer	1.64e-05	0.0144	CrCbGaD
Bosutinib—CSF1R—lymph node—lung cancer	1.61e-05	0.000663	CbGeAlD
Bosutinib—CHEK2—Podofilox—Teniposide—lung cancer	1.58e-05	0.0175	CbGdCrCtD
Bosutinib—Fatigue—Gemcitabine—lung cancer	1.56e-05	0.00052	CcSEcCtD
Bosutinib—Pain—Gemcitabine—lung cancer	1.55e-05	0.000516	CcSEcCtD
Bosutinib—Nausea—Erlotinib—lung cancer	1.55e-05	0.000516	CcSEcCtD
Bosutinib—Pancytopenia—Methotrexate—lung cancer	1.55e-05	0.000516	CcSEcCtD
Bosutinib—Anaphylactic shock—Etoposide—lung cancer	1.55e-05	0.000515	CcSEcCtD
Bosutinib—Diarrhoea—Vinorelbine—lung cancer	1.54e-05	0.000514	CcSEcCtD
Bosutinib—Dysgeusia—Docetaxel—lung cancer	1.54e-05	0.000514	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Cisplatin—lung cancer	1.54e-05	0.000513	CcSEcCtD
Bosutinib—Infection—Etoposide—lung cancer	1.54e-05	0.000512	CcSEcCtD
Bosutinib—Feeling abnormal—Irinotecan—lung cancer	1.53e-05	0.000511	CcSEcCtD
Bosutinib—Blood creatinine increased—Doxorubicin—lung cancer	1.53e-05	0.000509	CcSEcCtD
Bosutinib—Back pain—Docetaxel—lung cancer	1.52e-05	0.000508	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—lung cancer	1.52e-05	0.000508	CcSEcCtD
Bosutinib—Gastrointestinal pain—Irinotecan—lung cancer	1.52e-05	0.000507	CcSEcCtD
Bosutinib—CAMK2G—Azacitidine—Gemcitabine—lung cancer	1.52e-05	0.0168	CbGdCrCtD
Bosutinib—Dehydration—Doxorubicin—lung cancer	1.52e-05	0.000506	CcSEcCtD
Bosutinib—Anaphylactic shock—Paclitaxel—lung cancer	1.52e-05	0.000505	CcSEcCtD
Bosutinib—Oedema—Paclitaxel—lung cancer	1.52e-05	0.000505	CcSEcCtD
Bosutinib—Thrombocytopenia—Etoposide—lung cancer	1.51e-05	0.000505	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Methotrexate—lung cancer	1.51e-05	0.000505	CcSEcCtD
Bosutinib—Infection—Paclitaxel—lung cancer	1.51e-05	0.000502	CcSEcCtD
Bosutinib—Dyspnoea—Cisplatin—lung cancer	1.51e-05	0.000502	CcSEcCtD
Bosutinib—Skin disorder—Etoposide—lung cancer	1.5e-05	0.000501	CcSEcCtD
Bosutinib—CHEK2—Vindesine—Vinblastine—lung cancer	1.49e-05	0.0165	CbGdCrCtD
Bosutinib—Feeling abnormal—Gemcitabine—lung cancer	1.49e-05	0.000497	CcSEcCtD
Bosutinib—Dizziness—Vinorelbine—lung cancer	1.49e-05	0.000497	CcSEcCtD
Bosutinib—Abdominal pain upper—Doxorubicin—lung cancer	1.49e-05	0.000497	CcSEcCtD
Bosutinib—Nervous system disorder—Paclitaxel—lung cancer	1.49e-05	0.000496	CcSEcCtD
Bosutinib—Thrombocytopenia—Paclitaxel—lung cancer	1.49e-05	0.000495	CcSEcCtD
Bosutinib—Skin disorder—Paclitaxel—lung cancer	1.47e-05	0.000491	CcSEcCtD
Bosutinib—Abdominal pain—Irinotecan—lung cancer	1.47e-05	0.00049	CcSEcCtD
Bosutinib—Body temperature increased—Irinotecan—lung cancer	1.47e-05	0.00049	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—lung cancer	1.47e-05	0.00049	CcSEcCtD
Bosutinib—Decreased appetite—Cisplatin—lung cancer	1.47e-05	0.000489	CcSEcCtD
Bosutinib—CHEK2—Paclitaxel—Docetaxel—lung cancer	1.47e-05	0.0162	CbGdCrCtD
Bosutinib—Pneumonia—Methotrexate—lung cancer	1.46e-05	0.000487	CcSEcCtD
Bosutinib—Nasopharyngitis—Doxorubicin—lung cancer	1.46e-05	0.000486	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Cisplatin—lung cancer	1.46e-05	0.000486	CcSEcCtD
Bosutinib—Anaemia—Docetaxel—lung cancer	1.46e-05	0.000485	CcSEcCtD
Bosutinib—Infestation NOS—Methotrexate—lung cancer	1.45e-05	0.000484	CcSEcCtD
Bosutinib—Infestation—Methotrexate—lung cancer	1.45e-05	0.000484	CcSEcCtD
Bosutinib—Gastritis—Doxorubicin—lung cancer	1.44e-05	0.000481	CcSEcCtD
Bosutinib—Pain—Cisplatin—lung cancer	1.44e-05	0.000481	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—lung cancer	1.44e-05	0.00048	CcSEcCtD
Bosutinib—Vomiting—Vinorelbine—lung cancer	1.43e-05	0.000478	CcSEcCtD
Bosutinib—Body temperature increased—Gemcitabine—lung cancer	1.43e-05	0.000477	CcSEcCtD
Bosutinib—Renal failure—Methotrexate—lung cancer	1.43e-05	0.000476	CcSEcCtD
Bosutinib—PDGFRB—lymph node—lung cancer	1.43e-05	0.000588	CbGeAlD
Bosutinib—Rash—Vinorelbine—lung cancer	1.42e-05	0.000474	CcSEcCtD
Bosutinib—Dermatitis—Vinorelbine—lung cancer	1.42e-05	0.000473	CcSEcCtD
Bosutinib—Headache—Vinorelbine—lung cancer	1.41e-05	0.000471	CcSEcCtD
Bosutinib—Influenza—Doxorubicin—lung cancer	1.41e-05	0.00047	CcSEcCtD
Bosutinib—Leukopenia—Docetaxel—lung cancer	1.41e-05	0.00047	CcSEcCtD
Bosutinib—ERBB3—Podofilox—Etoposide—lung cancer	1.4e-05	0.0154	CbGdCrCtD
Bosutinib—Feeling abnormal—Cisplatin—lung cancer	1.39e-05	0.000464	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Paclitaxel—lung cancer	1.38e-05	0.00046	CcSEcCtD
Bosutinib—Dyspnoea—Etoposide—lung cancer	1.38e-05	0.000459	CcSEcCtD
Bosutinib—Cough—Docetaxel—lung cancer	1.37e-05	0.000458	CcSEcCtD
Bosutinib—Hepatobiliary disease—Methotrexate—lung cancer	1.37e-05	0.000458	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—lung cancer	1.36e-05	0.000452	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—lung cancer	1.36e-05	0.000452	CcSEcCtD
Bosutinib—Dyspnoea—Paclitaxel—lung cancer	1.35e-05	0.00045	CcSEcCtD
Bosutinib—Decreased appetite—Etoposide—lung cancer	1.34e-05	0.000448	CcSEcCtD
Bosutinib—Arthralgia—Docetaxel—lung cancer	1.34e-05	0.000447	CcSEcCtD
Bosutinib—Chest pain—Docetaxel—lung cancer	1.34e-05	0.000447	CcSEcCtD
Bosutinib—Myalgia—Docetaxel—lung cancer	1.34e-05	0.000447	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—lung cancer	1.34e-05	0.000446	CcSEcCtD
Bosutinib—Nausea—Vinorelbine—lung cancer	1.34e-05	0.000446	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Etoposide—lung cancer	1.34e-05	0.000445	CcSEcCtD
Bosutinib—Body temperature increased—Cisplatin—lung cancer	1.34e-05	0.000445	CcSEcCtD
Bosutinib—Asthenia—Irinotecan—lung cancer	1.33e-05	0.000445	CcSEcCtD
Bosutinib—Fatigue—Etoposide—lung cancer	1.33e-05	0.000444	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	1.33e-05	0.000444	CcSEcCtD
Bosutinib—Pain—Etoposide—lung cancer	1.32e-05	0.000441	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—lung cancer	1.32e-05	0.00044	CcSEcCtD
Bosutinib—Decreased appetite—Paclitaxel—lung cancer	1.32e-05	0.000439	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—lung cancer	1.31e-05	0.000437	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Paclitaxel—lung cancer	1.31e-05	0.000436	CcSEcCtD
Bosutinib—Fatigue—Paclitaxel—lung cancer	1.31e-05	0.000436	CcSEcCtD
Bosutinib—Hepatitis—Methotrexate—lung cancer	1.3e-05	0.000434	CcSEcCtD
Bosutinib—Asthenia—Gemcitabine—lung cancer	1.3e-05	0.000433	CcSEcCtD
Bosutinib—Pain—Paclitaxel—lung cancer	1.3e-05	0.000432	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—lung cancer	1.29e-05	0.000429	CcSEcCtD
Bosutinib—Anaphylactic shock—Docetaxel—lung cancer	1.29e-05	0.000428	CcSEcCtD
Bosutinib—Oedema—Docetaxel—lung cancer	1.29e-05	0.000428	CcSEcCtD
Bosutinib—Pruritus—Gemcitabine—lung cancer	1.28e-05	0.000427	CcSEcCtD
Bosutinib—Urethral disorder—Methotrexate—lung cancer	1.28e-05	0.000426	CcSEcCtD
Bosutinib—Infection—Docetaxel—lung cancer	1.28e-05	0.000425	CcSEcCtD
Bosutinib—Feeling abnormal—Etoposide—lung cancer	1.27e-05	0.000425	CcSEcCtD
Bosutinib—ABL1—lymph node—lung cancer	1.27e-05	0.000524	CbGeAlD
Bosutinib—Diarrhoea—Irinotecan—lung cancer	1.27e-05	0.000424	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—lung cancer	1.27e-05	0.000422	CcSEcCtD
Bosutinib—Gastrointestinal pain—Etoposide—lung cancer	1.27e-05	0.000421	CcSEcCtD
Bosutinib—Nervous system disorder—Docetaxel—lung cancer	1.26e-05	0.00042	CcSEcCtD
Bosutinib—Thrombocytopenia—Docetaxel—lung cancer	1.26e-05	0.000419	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—lung cancer	1.26e-05	0.000419	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—lung cancer	1.26e-05	0.000419	CcSEcCtD
Bosutinib—Feeling abnormal—Paclitaxel—lung cancer	1.25e-05	0.000416	CcSEcCtD
Bosutinib—Skin disorder—Docetaxel—lung cancer	1.25e-05	0.000416	CcSEcCtD
Bosutinib—Gastrointestinal pain—Paclitaxel—lung cancer	1.24e-05	0.000413	CcSEcCtD
Bosutinib—Diarrhoea—Gemcitabine—lung cancer	1.24e-05	0.000413	CcSEcCtD
Bosutinib—Renal failure—Doxorubicin—lung cancer	1.24e-05	0.000412	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—lung cancer	1.23e-05	0.000411	CcSEcCtD
Bosutinib—Dizziness—Irinotecan—lung cancer	1.23e-05	0.00041	CcSEcCtD
Bosutinib—Urticaria—Etoposide—lung cancer	1.23e-05	0.000409	CcSEcCtD
Bosutinib—Body temperature increased—Etoposide—lung cancer	1.22e-05	0.000407	CcSEcCtD
Bosutinib—Abdominal pain—Etoposide—lung cancer	1.22e-05	0.000407	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—lung cancer	1.22e-05	0.000405	CcSEcCtD
Bosutinib—Asthenia—Cisplatin—lung cancer	1.21e-05	0.000404	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—lung cancer	1.21e-05	0.000403	CcSEcCtD
Bosutinib—Urticaria—Paclitaxel—lung cancer	1.21e-05	0.000401	CcSEcCtD
Bosutinib—ERBB3—Vinblastine—Vinorelbine—lung cancer	1.2e-05	0.0133	CbGdCrCtD
Bosutinib—Body temperature increased—Paclitaxel—lung cancer	1.2e-05	0.000399	CcSEcCtD
Bosutinib—Abdominal pain—Paclitaxel—lung cancer	1.2e-05	0.000399	CcSEcCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—lung cancer	1.19e-05	0.000396	CcSEcCtD
Bosutinib—Vomiting—Irinotecan—lung cancer	1.18e-05	0.000394	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—lung cancer	1.18e-05	0.000392	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—lung cancer	1.18e-05	0.000392	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—lung cancer	1.17e-05	0.000391	CcSEcCtD
Bosutinib—Rash—Irinotecan—lung cancer	1.17e-05	0.000391	CcSEcCtD
Bosutinib—Dermatitis—Irinotecan—lung cancer	1.17e-05	0.00039	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Docetaxel—lung cancer	1.17e-05	0.00039	CcSEcCtD
Bosutinib—Headache—Irinotecan—lung cancer	1.17e-05	0.000388	CcSEcCtD
Bosutinib—Diarrhoea—Cisplatin—lung cancer	1.16e-05	0.000385	CcSEcCtD
Bosutinib—Vomiting—Gemcitabine—lung cancer	1.15e-05	0.000384	CcSEcCtD
Bosutinib—Dyspnoea—Docetaxel—lung cancer	1.15e-05	0.000382	CcSEcCtD
Bosutinib—Rash—Gemcitabine—lung cancer	1.14e-05	0.000381	CcSEcCtD
Bosutinib—Dermatitis—Gemcitabine—lung cancer	1.14e-05	0.00038	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—lung cancer	1.14e-05	0.000378	CcSEcCtD
Bosutinib—Headache—Gemcitabine—lung cancer	1.14e-05	0.000378	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—lung cancer	1.13e-05	0.000376	CcSEcCtD
Bosutinib—Decreased appetite—Docetaxel—lung cancer	1.12e-05	0.000372	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—lung cancer	1.12e-05	0.000372	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—lung cancer	1.11e-05	0.000371	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—lung cancer	1.11e-05	0.00037	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Docetaxel—lung cancer	1.11e-05	0.00037	CcSEcCtD
Bosutinib—Asthenia—Etoposide—lung cancer	1.11e-05	0.00037	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—lung cancer	1.11e-05	0.00037	CcSEcCtD
Bosutinib—Fatigue—Docetaxel—lung cancer	1.11e-05	0.000369	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—lung cancer	1.11e-05	0.000369	CcSEcCtD
Bosutinib—Nausea—Irinotecan—lung cancer	1.1e-05	0.000368	CcSEcCtD
Bosutinib—Pain—Docetaxel—lung cancer	1.1e-05	0.000366	CcSEcCtD
Bosutinib—Back pain—Methotrexate—lung cancer	1.1e-05	0.000366	CcSEcCtD
Bosutinib—Pruritus—Etoposide—lung cancer	1.09e-05	0.000365	CcSEcCtD
Bosutinib—ABCB1—respiratory system—lung cancer	1.09e-05	0.000449	CbGeAlD
Bosutinib—Asthenia—Paclitaxel—lung cancer	1.09e-05	0.000363	CcSEcCtD
Bosutinib—Nausea—Gemcitabine—lung cancer	1.08e-05	0.000358	CcSEcCtD
Bosutinib—Vomiting—Cisplatin—lung cancer	1.07e-05	0.000358	CcSEcCtD
Bosutinib—Pruritus—Paclitaxel—lung cancer	1.07e-05	0.000357	CcSEcCtD
Bosutinib—Erythema multiforme—Doxorubicin—lung cancer	1.07e-05	0.000356	CcSEcCtD
Bosutinib—Rash—Cisplatin—lung cancer	1.06e-05	0.000355	CcSEcCtD
Bosutinib—Dermatitis—Cisplatin—lung cancer	1.06e-05	0.000354	CcSEcCtD
Bosutinib—Feeling abnormal—Docetaxel—lung cancer	1.06e-05	0.000353	CcSEcCtD
Bosutinib—Diarrhoea—Etoposide—lung cancer	1.06e-05	0.000353	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—lung cancer	1.05e-05	0.000351	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—lung cancer	1.05e-05	0.000351	CcSEcCtD
Bosutinib—Gastrointestinal pain—Docetaxel—lung cancer	1.05e-05	0.00035	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—lung cancer	1.05e-05	0.00035	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—lung cancer	1.05e-05	0.000349	CcSEcCtD
Bosutinib—Diarrhoea—Paclitaxel—lung cancer	1.04e-05	0.000346	CcSEcCtD
Bosutinib—Malaise—Methotrexate—lung cancer	1.02e-05	0.000341	CcSEcCtD
Bosutinib—Dizziness—Etoposide—lung cancer	1.02e-05	0.000341	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—lung cancer	1.02e-05	0.00034	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—lung cancer	1.02e-05	0.000339	CcSEcCtD
Bosutinib—Body temperature increased—Docetaxel—lung cancer	1.02e-05	0.000339	CcSEcCtD
Bosutinib—Abdominal pain—Docetaxel—lung cancer	1.02e-05	0.000339	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—lung cancer	1.02e-05	0.000339	CcSEcCtD
Bosutinib—CHEK2—Vincristine—Vinorelbine—lung cancer	1.01e-05	0.0111	CbGdCrCtD
Bosutinib—Dizziness—Paclitaxel—lung cancer	1e-05	0.000334	CcSEcCtD
Bosutinib—Nausea—Cisplatin—lung cancer	1e-05	0.000334	CcSEcCtD
Bosutinib—Cough—Methotrexate—lung cancer	9.91e-06	0.00033	CcSEcCtD
Bosutinib—Vomiting—Etoposide—lung cancer	9.84e-06	0.000328	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—lung cancer	9.83e-06	0.000328	CcSEcCtD
Bosutinib—Rash—Etoposide—lung cancer	9.76e-06	0.000325	CcSEcCtD
Bosutinib—Dermatitis—Etoposide—lung cancer	9.75e-06	0.000325	CcSEcCtD
Bosutinib—Headache—Etoposide—lung cancer	9.69e-06	0.000323	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—lung cancer	9.67e-06	0.000322	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—lung cancer	9.67e-06	0.000322	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—lung cancer	9.67e-06	0.000322	CcSEcCtD
Bosutinib—Vomiting—Paclitaxel—lung cancer	9.65e-06	0.000321	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—lung cancer	9.63e-06	0.000321	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	9.6e-06	0.00032	CcSEcCtD
Bosutinib—Rash—Paclitaxel—lung cancer	9.56e-06	0.000319	CcSEcCtD
Bosutinib—Dermatitis—Paclitaxel—lung cancer	9.56e-06	0.000318	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—lung cancer	9.55e-06	0.000318	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—lung cancer	9.51e-06	0.000317	CcSEcCtD
Bosutinib—Headache—Paclitaxel—lung cancer	9.5e-06	0.000317	CcSEcCtD
Bosutinib—CHEK2—Vinorelbine—Vinblastine—lung cancer	9.43e-06	0.0104	CbGdCrCtD
Bosutinib—CHEK2—Teniposide—Etoposide—lung cancer	9.42e-06	0.0104	CbGdCrCtD
Bosutinib—CHEK2—Podofilox—Etoposide—lung cancer	9.42e-06	0.0104	CbGdCrCtD
Bosutinib—Anaphylactic shock—Methotrexate—lung cancer	9.27e-06	0.000309	CcSEcCtD
Bosutinib—Asthenia—Docetaxel—lung cancer	9.23e-06	0.000307	CcSEcCtD
Bosutinib—Infection—Methotrexate—lung cancer	9.21e-06	0.000307	CcSEcCtD
Bosutinib—Nausea—Etoposide—lung cancer	9.19e-06	0.000306	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—lung cancer	9.12e-06	0.000304	CcSEcCtD
Bosutinib—ABCB1—epithelium—lung cancer	9.11e-06	0.000375	CbGeAlD
Bosutinib—Pruritus—Docetaxel—lung cancer	9.1e-06	0.000303	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—lung cancer	9.09e-06	0.000303	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—lung cancer	9.09e-06	0.000303	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—lung cancer	9.07e-06	0.000302	CcSEcCtD
Bosutinib—Nausea—Paclitaxel—lung cancer	9.01e-06	0.0003	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—lung cancer	9e-06	0.0003	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—lung cancer	8.87e-06	0.000295	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—lung cancer	8.8e-06	0.000293	CcSEcCtD
Bosutinib—Diarrhoea—Docetaxel—lung cancer	8.8e-06	0.000293	CcSEcCtD
Bosutinib—Cough—Doxorubicin—lung cancer	8.58e-06	0.000286	CcSEcCtD
Bosutinib—Dizziness—Docetaxel—lung cancer	8.5e-06	0.000283	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—lung cancer	8.44e-06	0.000281	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—lung cancer	8.37e-06	0.000279	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—lung cancer	8.37e-06	0.000279	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—lung cancer	8.37e-06	0.000279	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	8.31e-06	0.000277	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—lung cancer	8.27e-06	0.000275	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—lung cancer	8.26e-06	0.000275	CcSEcCtD
Bosutinib—Vomiting—Docetaxel—lung cancer	8.18e-06	0.000272	CcSEcCtD
Bosutinib—CHEK2—Vinblastine—Vinorelbine—lung cancer	8.11e-06	0.00895	CbGdCrCtD
Bosutinib—Rash—Docetaxel—lung cancer	8.11e-06	0.00027	CcSEcCtD
Bosutinib—Dermatitis—Docetaxel—lung cancer	8.1e-06	0.00027	CcSEcCtD
Bosutinib—CHEK2—Vincristine—Vinblastine—lung cancer	8.06e-06	0.0089	CbGdCrCtD
Bosutinib—Decreased appetite—Methotrexate—lung cancer	8.06e-06	0.000268	CcSEcCtD
Bosutinib—Headache—Docetaxel—lung cancer	8.06e-06	0.000268	CcSEcCtD
Bosutinib—ABCB1—trachea—lung cancer	8.05e-06	0.000332	CbGeAlD
Bosutinib—Oedema—Doxorubicin—lung cancer	8.02e-06	0.000267	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—lung cancer	8.02e-06	0.000267	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—lung cancer	8e-06	0.000267	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—lung cancer	7.99e-06	0.000266	CcSEcCtD
Bosutinib—Infection—Doxorubicin—lung cancer	7.97e-06	0.000266	CcSEcCtD
Bosutinib—Pain—Methotrexate—lung cancer	7.93e-06	0.000264	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—lung cancer	7.87e-06	0.000262	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—lung cancer	7.86e-06	0.000262	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—lung cancer	7.79e-06	0.00026	CcSEcCtD
Bosutinib—Nausea—Docetaxel—lung cancer	7.64e-06	0.000254	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—lung cancer	7.64e-06	0.000254	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—lung cancer	7.58e-06	0.000252	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—lung cancer	7.36e-06	0.000245	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—lung cancer	7.33e-06	0.000244	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—lung cancer	7.33e-06	0.000244	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—lung cancer	7.31e-06	0.000244	CcSEcCtD
Bosutinib—Dyspnoea—Doxorubicin—lung cancer	7.15e-06	0.000238	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—lung cancer	6.98e-06	0.000232	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—lung cancer	6.93e-06	0.000231	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—lung cancer	6.92e-06	0.00023	CcSEcCtD
Bosutinib—Pain—Doxorubicin—lung cancer	6.86e-06	0.000229	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—lung cancer	6.65e-06	0.000221	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—lung cancer	6.61e-06	0.00022	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—lung cancer	6.56e-06	0.000219	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—lung cancer	6.56e-06	0.000218	CcSEcCtD
Bosutinib—ABCB1—bone marrow—lung cancer	6.39e-06	0.000263	CbGeAlD
Bosutinib—Urticaria—Doxorubicin—lung cancer	6.37e-06	0.000212	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—lung cancer	6.34e-06	0.000211	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—lung cancer	6.34e-06	0.000211	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—lung cancer	6.34e-06	0.000211	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—lung cancer	6.21e-06	0.00686	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—lung cancer	6.21e-06	0.00686	CbGdCrCtD
Bosutinib—Dizziness—Methotrexate—lung cancer	6.13e-06	0.000204	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—lung cancer	5.89e-06	0.000196	CcSEcCtD
Bosutinib—Rash—Methotrexate—lung cancer	5.84e-06	0.000195	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—lung cancer	5.84e-06	0.000194	CcSEcCtD
Bosutinib—Headache—Methotrexate—lung cancer	5.81e-06	0.000193	CcSEcCtD
Bosutinib—ABCB1—lung—lung cancer	5.79e-06	0.000238	CbGeAlD
Bosutinib—Asthenia—Doxorubicin—lung cancer	5.76e-06	0.000192	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—lung cancer	5.68e-06	0.000189	CcSEcCtD
Bosutinib—Nausea—Methotrexate—lung cancer	5.5e-06	0.000183	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—lung cancer	5.49e-06	0.000183	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—lung cancer	5.31e-06	0.000177	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—lung cancer	5.1e-06	0.00017	CcSEcCtD
Bosutinib—Rash—Doxorubicin—lung cancer	5.06e-06	0.000169	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—lung cancer	5.06e-06	0.000168	CcSEcCtD
Bosutinib—Headache—Doxorubicin—lung cancer	5.03e-06	0.000167	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—lung cancer	4.77e-06	0.000159	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—lung cancer	4.55e-06	0.00502	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—lung cancer	4.34e-06	0.00479	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—lung cancer	4.34e-06	0.00479	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—lung cancer	4.34e-06	0.00479	CbGdCrCtD
Bosutinib—ABCB1—lymph node—lung cancer	3.96e-06	0.000163	CbGeAlD
Bosutinib—LCK—Signaling Pathways—PIK3CB—lung cancer	7.13e-08	1.59e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MTOR—lung cancer	7.13e-08	1.59e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—lung cancer	7.13e-08	1.59e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SRC—lung cancer	7.12e-08	1.59e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ENO1—lung cancer	7.12e-08	1.59e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—lung cancer	7.11e-08	1.59e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—lung cancer	7.11e-08	1.59e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—lung cancer	7.11e-08	1.59e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—lung cancer	7.11e-08	1.59e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—lung cancer	7.07e-08	1.58e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EP300—lung cancer	7.06e-08	1.58e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—lung cancer	7.04e-08	1.57e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EP300—lung cancer	7.02e-08	1.57e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—lung cancer	7.02e-08	1.57e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—lung cancer	7.02e-08	1.57e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—lung cancer	7.02e-08	1.57e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—lung cancer	7.01e-08	1.57e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—lung cancer	6.98e-08	1.56e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—lung cancer	6.98e-08	1.56e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SRC—lung cancer	6.97e-08	1.56e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—lung cancer	6.97e-08	1.56e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—lung cancer	6.95e-08	1.55e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—lung cancer	6.94e-08	1.55e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—lung cancer	6.92e-08	1.54e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—lung cancer	6.9e-08	1.54e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—lung cancer	6.88e-08	1.54e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—lung cancer	6.87e-08	1.53e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—lung cancer	6.87e-08	1.53e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—lung cancer	6.87e-08	1.53e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SRC—lung cancer	6.87e-08	1.53e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—lung cancer	6.86e-08	1.53e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—lung cancer	6.86e-08	1.53e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—lung cancer	6.85e-08	1.53e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—lung cancer	6.85e-08	1.53e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—lung cancer	6.85e-08	1.53e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—lung cancer	6.85e-08	1.53e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SRC—lung cancer	6.83e-08	1.53e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—lung cancer	6.81e-08	1.52e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—lung cancer	6.8e-08	1.52e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—lung cancer	6.79e-08	1.52e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—lung cancer	6.76e-08	1.51e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—lung cancer	6.76e-08	1.51e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—lung cancer	6.75e-08	1.51e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—lung cancer	6.73e-08	1.5e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—lung cancer	6.73e-08	1.5e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK3—lung cancer	6.72e-08	1.5e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—lung cancer	6.71e-08	1.5e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—lung cancer	6.7e-08	1.5e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—lung cancer	6.69e-08	1.49e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—lung cancer	6.67e-08	1.49e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—lung cancer	6.67e-08	1.49e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK3—lung cancer	6.66e-08	1.49e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—lung cancer	6.65e-08	1.49e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—lung cancer	6.63e-08	1.48e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—lung cancer	6.62e-08	1.48e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—lung cancer	6.62e-08	1.48e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—JUN—lung cancer	6.61e-08	1.48e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—lung cancer	6.6e-08	1.48e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—lung cancer	6.6e-08	1.48e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—lung cancer	6.6e-08	1.47e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—lung cancer	6.59e-08	1.47e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—lung cancer	6.58e-08	1.47e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—lung cancer	6.57e-08	1.47e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—lung cancer	6.57e-08	1.47e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—lung cancer	6.56e-08	1.47e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK3—lung cancer	6.56e-08	1.47e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—lung cancer	6.56e-08	1.47e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—lung cancer	6.55e-08	1.46e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—lung cancer	6.54e-08	1.46e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—lung cancer	6.53e-08	1.46e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MDM2—lung cancer	6.49e-08	1.45e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—lung cancer	6.48e-08	1.45e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—lung cancer	6.48e-08	1.45e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—lung cancer	6.48e-08	1.45e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RAF1—lung cancer	6.47e-08	1.44e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—lung cancer	6.46e-08	1.44e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—lung cancer	6.44e-08	1.44e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—lung cancer	6.43e-08	1.44e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK3—lung cancer	6.43e-08	1.44e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1A—lung cancer	6.41e-08	1.43e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—lung cancer	6.4e-08	1.43e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—lung cancer	6.4e-08	1.43e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—lung cancer	6.4e-08	1.43e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—lung cancer	6.39e-08	1.43e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOA1—lung cancer	6.39e-08	1.43e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—lung cancer	6.39e-08	1.43e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP2E1—lung cancer	6.38e-08	1.43e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—lung cancer	6.38e-08	1.43e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—JUN—lung cancer	6.37e-08	1.42e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—lung cancer	6.35e-08	1.42e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—lung cancer	6.33e-08	1.41e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK3—lung cancer	6.33e-08	1.41e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—lung cancer	6.32e-08	1.41e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CB—lung cancer	6.31e-08	1.41e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MTOR—lung cancer	6.31e-08	1.41e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NQO1—lung cancer	6.31e-08	1.41e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—lung cancer	6.3e-08	1.41e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK3—lung cancer	6.29e-08	1.41e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—lung cancer	6.25e-08	1.4e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—lung cancer	6.24e-08	1.39e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—lung cancer	6.24e-08	1.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—lung cancer	6.24e-08	1.39e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—lung cancer	6.22e-08	1.39e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—lung cancer	6.21e-08	1.39e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—lung cancer	6.2e-08	1.38e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—lung cancer	6.18e-08	1.38e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1A—lung cancer	6.18e-08	1.38e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—lung cancer	6.16e-08	1.38e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—lung cancer	6.15e-08	1.37e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—lung cancer	6.15e-08	1.37e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—lung cancer	6.12e-08	1.37e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—lung cancer	6.11e-08	1.37e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EP300—lung cancer	6.1e-08	1.36e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—lung cancer	6.09e-08	1.36e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—lung cancer	6.07e-08	1.36e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—lung cancer	6.06e-08	1.35e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—lung cancer	6.04e-08	1.35e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—lung cancer	6.02e-08	1.34e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—lung cancer	5.99e-08	1.34e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—lung cancer	5.98e-08	1.34e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—lung cancer	5.98e-08	1.33e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—lung cancer	5.96e-08	1.33e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—lung cancer	5.96e-08	1.33e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—lung cancer	5.95e-08	1.33e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SRC—lung cancer	5.93e-08	1.32e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—lung cancer	5.9e-08	1.32e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—lung cancer	5.89e-08	1.32e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—lung cancer	5.88e-08	1.31e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EP300—lung cancer	5.88e-08	1.31e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—lung cancer	5.83e-08	1.3e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—lung cancer	5.81e-08	1.3e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—lung cancer	5.81e-08	1.3e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—lung cancer	5.8e-08	1.3e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—lung cancer	5.78e-08	1.29e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—lung cancer	5.77e-08	1.29e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—lung cancer	5.74e-08	1.28e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—lung cancer	5.72e-08	1.28e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SRC—lung cancer	5.72e-08	1.28e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—lung cancer	5.71e-08	1.27e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—lung cancer	5.71e-08	1.27e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—lung cancer	5.7e-08	1.27e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—STK11—lung cancer	5.69e-08	1.27e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—lung cancer	5.68e-08	1.27e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—lung cancer	5.65e-08	1.26e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—lung cancer	5.65e-08	1.26e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JUN—lung cancer	5.64e-08	1.26e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—lung cancer	5.63e-08	1.26e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—lung cancer	5.57e-08	1.24e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—lung cancer	5.55e-08	1.24e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—POMC—lung cancer	5.55e-08	1.24e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—lung cancer	5.51e-08	1.23e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—lung cancer	5.51e-08	1.23e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—lung cancer	5.51e-08	1.23e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—lung cancer	5.5e-08	1.23e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—lung cancer	5.5e-08	1.23e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—lung cancer	5.5e-08	1.23e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—lung cancer	5.49e-08	1.23e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—lung cancer	5.49e-08	1.23e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1A—lung cancer	5.47e-08	1.22e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK3—lung cancer	5.46e-08	1.22e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—lung cancer	5.46e-08	1.22e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—lung cancer	5.42e-08	1.21e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CREBBP—lung cancer	5.41e-08	1.21e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—lung cancer	5.37e-08	1.2e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—lung cancer	5.32e-08	1.19e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—lung cancer	5.3e-08	1.18e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—lung cancer	5.27e-08	1.18e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK3—lung cancer	5.27e-08	1.18e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTP1—lung cancer	5.26e-08	1.18e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—lung cancer	5.26e-08	1.18e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—lung cancer	5.24e-08	1.17e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—lung cancer	5.22e-08	1.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EP300—lung cancer	5.2e-08	1.16e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—lung cancer	5.19e-08	1.16e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—lung cancer	5.19e-08	1.16e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—lung cancer	5.14e-08	1.15e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—lung cancer	5.13e-08	1.15e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CD—lung cancer	5.13e-08	1.14e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CAT—lung cancer	5.12e-08	1.14e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—lung cancer	5.12e-08	1.14e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—lung cancer	5.09e-08	1.14e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—lung cancer	5.07e-08	1.13e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—lung cancer	5.06e-08	1.13e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—lung cancer	5.05e-08	1.13e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—lung cancer	5.03e-08	1.12e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—lung cancer	5.01e-08	1.12e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—lung cancer	5.01e-08	1.12e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCB1—lung cancer	4.98e-08	1.11e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—lung cancer	4.93e-08	1.1e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—lung cancer	4.92e-08	1.1e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—lung cancer	4.91e-08	1.1e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—lung cancer	4.91e-08	1.1e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TYMS—lung cancer	4.89e-08	1.09e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—lung cancer	4.88e-08	1.09e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—lung cancer	4.87e-08	1.09e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—lung cancer	4.87e-08	1.09e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—lung cancer	4.86e-08	1.09e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTM1—lung cancer	4.84e-08	1.08e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—lung cancer	4.83e-08	1.08e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—lung cancer	4.81e-08	1.07e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—lung cancer	4.8e-08	1.07e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—lung cancer	4.73e-08	1.06e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—lung cancer	4.7e-08	1.05e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK3—lung cancer	4.66e-08	1.04e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—lung cancer	4.62e-08	1.03e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—lung cancer	4.6e-08	1.03e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1A1—lung cancer	4.59e-08	1.02e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ERCC2—lung cancer	4.55e-08	1.02e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—lung cancer	4.54e-08	1.01e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—lung cancer	4.53e-08	1.01e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—lung cancer	4.51e-08	1.01e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—lung cancer	4.49e-08	1e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CB—lung cancer	4.47e-08	9.98e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—lung cancer	4.44e-08	9.91e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—lung cancer	4.43e-08	9.89e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—lung cancer	4.43e-08	9.89e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—lung cancer	4.36e-08	9.75e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—lung cancer	4.35e-08	9.71e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—lung cancer	4.33e-08	9.68e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—lung cancer	4.27e-08	9.53e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—lung cancer	4.24e-08	9.48e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—lung cancer	4.21e-08	9.4e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—lung cancer	4.19e-08	9.36e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—lung cancer	4.17e-08	9.32e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—lung cancer	4.02e-08	8.99e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—lung cancer	4e-08	8.92e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOA1—lung cancer	3.93e-08	8.79e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—lung cancer	3.86e-08	8.62e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—lung cancer	3.85e-08	8.6e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—lung cancer	3.85e-08	8.6e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—lung cancer	3.72e-08	8.32e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—lung cancer	3.69e-08	8.23e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—EP300—lung cancer	3.68e-08	8.22e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—lung cancer	3.59e-08	8.02e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—lung cancer	3.56e-08	7.95e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—lung cancer	3.55e-08	7.93e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—POMC—lung cancer	3.42e-08	7.64e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—lung cancer	3.41e-08	7.61e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CREBBP—lung cancer	3.33e-08	7.44e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CD—lung cancer	3.16e-08	7.05e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—lung cancer	3.14e-08	7.02e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—lung cancer	3.12e-08	6.96e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CB—lung cancer	2.75e-08	6.15e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—lung cancer	2.73e-08	6.09e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—lung cancer	2.72e-08	6.08e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—lung cancer	2.38e-08	5.31e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—EP300—lung cancer	2.27e-08	5.07e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—lung cancer	2.22e-08	4.97e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—lung cancer	1.68e-08	3.75e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—lung cancer	1.37e-08	3.06e-07	CbGpPWpGaD
